Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Chugai to Market Modified Version of Tamiflu in Japan
July 31, 2006
- World's 1st Transdermal Agent for AD under Development by Novartis
July 31, 2006
- Anti-Parkinson's Drug KW-6002 Expected to Become Major Product: Kyowa Hakko
July 31, 2006
- SELF-MEDICATION NEWS IN BRIEF
July 31, 2006
- Covance Dedicates Itself to Development Service
July 31, 2006
- REGULATORY NEWS IN BRIEF
July 31, 2006
- MEDICAL DEVICE NEWS IN BRIEF
July 31, 2006
- JPMA Petition Calls For Increases in PMDA Reviewers
July 31, 2006
- SEMINAR
July 31, 2006
- Anact C's Approval Recommended for Purpura Fulminans
July 31, 2006
- Japanese Breast Cancer Society Drug Treatment Guidelines Amended
July 31, 2006
- COMMENTARY an article
July 31, 2006
- Arteriosclerosis Treatment GL under Amendment
July 31, 2006
- 1st Committee Recommends 3 New Drugs for Approval
July 31, 2006
- Leukemia Treatment Advances with Approval of Glivec
July 31, 2006
- Korosho to Again Cut \220 Billion in Natural Hike in Social Security Spending in FY2007
July 31, 2006
- 14th Clinical Pharmacy Symposium
July 31, 2006
- SEMIANR
July 31, 2006
- NEW PRODUCTS
July 31, 2006
- BUSINESS NEWS IN BRIEF
July 31, 2006
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…